NASDAQ:DMRA | Free Cash Flow | Damora Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$20.6M
2025-12-31$566,000.00
2025-03-31-$2.44M
2024-12-31-$4.94M
2024-03-31-$5.94M
2023-12-31-$11.47M
2023-03-31-$9.13M
2022-12-31-$11.45M$41,000.00-$11.49M
2022-03-31-$6.8M$43,000.00-$6.84M
2021-12-31-$17.83M-$4,000.00-$17.83M
2021-03-31-$14.15M$65,000.00-$14.22M
2020-12-31-$14.52M
2020-03-31-$7.98M
2019-12-31-$5.25M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$6.73M
2024-12-31-$18.62M
2023-12-31-$36.91M
2022-12-31-$42.93M$196,000.00-$43.13M
2021-12-31-$52.31M$223,000.00-$52.53M
2020-12-31-$38.2M
2019-12-31-$19.33M